Basic Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Jun 21, 2017; 23(23): 4181-4190
Published online Jun 21, 2017. doi: 10.3748/wjg.v23.i23.4181
Figure 6
Figure 6 Senicapoc prevents steatosis in the high fat diet Model. In animals fed a HFD for 6 wk, co-treatment with Senicapoc, A: Reduced NAS (0-8 scale); B: Decreased steatosis [H&E-stained section (40 ×) on left, steatosis score on right]; C: Decreased hepatic lipid content (Oil Red O- stained section (40 ×) on left; lipid vesicular area right); D: Six weeks on HFD is associated with inflammation (0-3 scale) which is mitigated with Senicapoc; and E: Senicapoc reduces F4/80 staining, a marker of macrophage activity, in the liver. aP < 0.05 vs vehicle. HFD: High fat diet.

Citation: Paka L, Smith DE, Jung D, McCormack S, Zhou P, Duan B, Li JS, Shi J, Hao YJ, Jiang K, Yamin M, Goldberg ID, Narayan P. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease. World J Gastroenterol 2017; 23(23): 4181-4190